Roche said Wednesday that it has entered a collaboration with drug maker Eli Lilly to support development of Roche's Elecsys Amyloid Plasma Panel (EAPP), a blood test for aiding earlier diagnosis of Alzheimer's disease.

Roche announced on Thursday that two of its tests for Alzheimer's disease have received 510(k) clearance from the US Food and Drug Administration.

The US Food and Drug Administration said on Wednesday it has issued de novo classification to Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio (1-42/1-40) test, allowing the company to market it as a tool for diagnosing Alzheimer's disease.

With the help of single-cell sequencing, a team from Boston Children's Hospital, the Broad Institute, Harvard Medical School, and elsewhere has found evidence for enhanced somatic mutation in brain cells from individuals with Alzheimer's disease.

While the word “mutation” may conjure up alarming notions, a mutation in brain immune cells serves a positive role in protecting people against Alzheimer’s disease.

Research has shown that an oxidation-antioxidant imbalance in the blood is an early indicator of Alzheimer's disease, rather than a consequence.

Early in the COVID-19 pandemic, individuals with Alzheimer's disease were identified as being at increased risk of developing severe COVID-19.

C2N Diagnostics is experiencing a couple of breakthroughs with its Alzheimers disease detection test - one courtesy of FDA. The agency, which is slowly rising back to full strength after the temporary government shutdown, granted the St. Lou

Brigham and Womens Hospital investigators are working on a test that could either diagnose or predict Alzheimers disease before symptoms appear. The investigators approach is in the December issue of Alzheimers Dementia. Tau proteins have lo